cannabidiol and REM-Sleep-Behavior-Disorder

REM sleep behaviour disorder (RBD) is a common non-motor feature of Parkinson's disease (PD). Cannabidiol (CBD) is one of the main non-psychoactive components of Cannabis sativa and may represent an alternative route for treating RBD.. This study assessed the efficacy and safety of CBD for RBD in PD.. We conducted a phase II/III, double-blind, placebo-controlled clinical trial in 33 patients with RBD and PD. Patients were randomized 1:1 to CBD in doses of 75 to 300mg or matched capsules placebo and were followed up for 14 weeks. The primary outcomes were the frequency of nights with RBD, CGI-I, and CGI-S.. CBD showed no difference to placebo for primary outcomes. Regarding secondary outcomes, we observed a significant improvement in average sleep satisfaction from the 4th to 8th week in the CBD versus placebo group with P = 0.049 and P = 0.038, respectively.. CBD, as an adjunct therapy, showed no reduction in RBD manifestations in PD patients. A transient improvement in sleep satisfaction with a dose of 300mg has been noted. © 2021 International Parkinson and Movement Disorder Society.

Topics: Cannabidiol; Humans; Parkinson Disease; REM Sleep Behavior Disorder

Cannabidiol (CBD) is the main non-psychotropic component of the Cannabis sativa plant. REM sleep behaviour disorder (RBD) is a parasomnia characterized by the loss of muscle atonia during REM sleep associated with nightmares and active behaviour during dreaming. We have described the effects of CBD in RBD symptoms in patients with Parkinson's disease.. Four patients treated with CBD had prompt and substantial reduction in the frequency of RBD-related events without side effects.. This case series indicates that CBD is able to control the symptoms of RBD.

Topics: Aged; Cannabidiol; Cannabis; Humans; Male; Middle Aged; Parkinson Disease; Phytotherapy; REM Sleep Behavior Disorder